Life Sciences

  • July 08, 2026

    Formula-Maker Sued After Recall And Reports Of Sick Infants

    Infant formula manufacturer Nara Organics Inc. sold milk-based powder that had to be recalled after federal regulators learned that multiple infants who had consumed the product were hospitalized with life-threatening botulism, according to a proposed class action filed Wednesday in New York federal court.

  • July 08, 2026

    PBMs Fight Bid To Add Pharmacy Group To Price-Fixing Suit

    Two pharmacy benefit managers have told a Michigan federal judge that a trade association for small pharmacies should not be allowed to intervene in a price-fixing lawsuit brought by the state's attorney general.

  • July 08, 2026

    Sheppard Adds Transactional, IP Attys In Chicago And San Diego

    Sheppard announced Wednesday that the firm has added an experienced intellectual property attorney focused on life sciences as a San Diego area-based partner, a day after announcing the addition of two Chicago-based transactional partners.

  • July 08, 2026

    Handa, Intas Face Patent Suits Over Exelixis Cancer Drug

    Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents on the medication expire, according to a new lawsuit in Delaware federal court.

  • July 08, 2026

    Biggest Rulings For Patent Attys In 2026: A Midyear Report

    The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the door to increased damages for patent owners. Here's what you need to know about these patent cases and other major decisions from the beginning of 2026.

  • July 07, 2026

    2 Ex-Telehealth Execs Sentenced For $100M Adderall Scheme

    A California federal judge on Tuesday sentenced two former executives of a telehealth company who were convicted of operating a $100 million scheme to illegally distribute Adderall over the internet, fining them $1 million each and giving the founder six years in prison.

  • July 07, 2026

    Illinois Cases To Watch In 2026: Midyear Report

    Mead Johnson is set to go to trial this summer in the first case to make it to a jury in multidistrict litigation claiming baby formula caused a serious gut illness in premature infants, while the U.S. attorney's office in Chicago is facing a possible sanctions hearing over prosecutorial misconduct allegations in two Illinois cases on attorneys' radar for the rest of the year.

  • July 07, 2026

    Regeneron Ducks Amgen's Eylea Antitrust Counterclaims

    A West Virginia federal judge dismissed key counterclaims and defenses Tuesday that Amgen had raised against Regeneron's patent infringement lawsuit targeting bids by multiple would-be rivals to produce biosimilar versions of eye medication Eylea, preserving only arguments that Regeneron waited too long to pursue the patent.

  • July 07, 2026

    CEO Cops To Conspiracy In BigLaw Insider Trading Case

    A Dubai-based CEO and trader has pled guilty in Massachusetts federal court to charges that he worked with a former BigLaw associate and others to carry out a far-reaching insider trading scheme.

  • July 07, 2026

    Align's Invisalign Patents Are Infringed But Invalid, Jury Finds

    A Texas federal jury has found that claims in four patents Invisalign maker Align Technology Inc. asserted against orthodontics company ClearCorrect were invalid, but the jurors also rejected ClearCorrect's antitrust claims against Align.

  • July 07, 2026

    Unstable Ex-Pfizer Office Spurs Evacuations In Manhattan

    The reported instability of pharmaceutical giant Pfizer's former New York City office headquarters, which is undergoing a conversion into residential units, led to the evacuations of multiple nearby buildings in Midtown Manhattan Tuesday.

  • July 07, 2026

    23andMe's $47M Data Breach Deal Gets Bankruptcy Court OK

    A Missouri bankruptcy judge entered an order Tuesday authorizing a $46.7 million settlement between the plan administration trust created under the Chapter 11 plan of DNA-testing company 23andMe and data breach claimants, finding the deal is fair and equitable. 

  • July 07, 2026

    Mayo Sacked Research Director For Flagging Flaws, Suit Says

    Mayo Clinic retaliated against and eventually terminated its director of research operations after she brought up concerns about security, safety and privacy regarding the medical center's use of artificial intelligence and other protocols, according to a lawsuit filed in Minnesota federal court on Monday.

  • July 07, 2026

    P&G Brushes Off Harm Of Toothpaste Ingredient, Suit Claims

    Procter & Gamble misleads consumers of its Crest Pro-Health toothpastes by failing to convey that the ingredient sodium lauryl sulfate can damage gum and mouth tissue and trigger inflammation — "the very conditions" the products are marketed as mitigating, a proposed class action alleges in California federal court.

  • July 07, 2026

    Groups Tell 4th Circ. Not To Let Sandoz 'Relitigate' Enbrel

    Pharmaceutical groups and the Washington Legal Foundation backed Amgen in amicus briefs Monday urging the Fourth Circuit not to revive Sandoz's antitrust claims, arguing that if Sandoz wanted to litigate blocked biosimilar competition to Enbrel, it needed to do so when Amgen sued it for patent infringement.

  • July 07, 2026

    5th Circ. Again Nixes Challenge To La. 340B Drug Delivery Law

    A Fifth Circuit panel doubled down on its decision to uphold a Louisiana law prohibiting drug manufacturers from blocking contracts between pharmacies and providers in the federal 340B drug discount program, reiterating that conclusion upon rehearing but this time allowing intervention by an advocacy group.

  • July 07, 2026

    Fed. Circ. Won't Revive Dental Patent Claims In Align Feud

    The Federal Circuit on Tuesday said it won't bring back claims in a pair of dental arch image analysis patents their owner accused Invisalign maker Align Technology Inc. of infringing, backing a lower court's finding that they were invalid.

  • July 07, 2026

    Longtime Goodwin Procter IP Lawyer Moves To Pillsbury In DC

    A career Goodwin Procter LLP lawyer, who spent nearly two decades at that firm working on high-stakes intellectual property disputes, has joined Pillsbury Winthrop Shaw Pittman LLP's Washington, D.C., office.

  • July 06, 2026

    CVS To Pay $36.5M To Settle States' Insulin FCA Suits

    CVS has agreed to shell out $36.5 million to put to rest a handful of False Claims Act suits from states and the federal government, which allege the pharmacy chain submitted fraudulent Medicaid claims after giving patients more insulin than they were prescribed and lying about refill timelines.

  • July 06, 2026

    3 Firms Guide Vertex's $10B Buy Of Crinetics Pharmaceuticals

    Kirkland & Ellis LLP is advising Vertex Pharmaceuticals Inc. in its $10 billion acquisition of Crinetics Pharmaceuticals Inc., which is being represented by both Paul Weiss Rifkind Wharton & Garrison LLP and Morrison Foerster LLP, according to an announcement made Monday.

  • July 06, 2026

    5,000 Pharmacies Accuse Prime Therapeutics Of Price-Fixing

    Nearly 5,000 pharmacies accuse Prime Therapeutics LLC of entering into an unlawful price-fixing agreement with rival pharmacy benefit manager Express Scripts Inc. to deflate pharmacies' reimbursement rates and inflate their fees, according to a new lawsuit filed in Seattle federal court.

  • July 06, 2026

    Medtronic Denied Bid To Nix $382M Antitrust Loss

    A California federal court has denied Medtronic Inc.'s attempt to ditch a roughly $382 million trial loss in an antitrust case accusing the company of maintaining its monopoly over a surgical device through contracts that a jury found blocked competition.

  • July 06, 2026

    Clarivate Sells Life Sciences And Healthcare Biz For $600M

    Analytics company Clarivate PLC on Monday announced that it has agreed to sell its Life Sciences & Healthcare segment to investment firm Altaris LLC in a $600 million deal built by three law firms.

  • July 06, 2026

    Latest Squires Order Accepts 9 Patent Petitions, Rejects 2

    The U.S. Patent and Trademark Office director granted nine petitions for America Invents Act patent scrutiny and denied two others, while also saying he'd assess the merits of a dozen other challenges.

  • July 06, 2026

    3M, Chubb Settle Suit Over Warming Device Defense Coverage

    3M Co. and Chubb unit Federal Insurance Co. reached a deal resolving a dispute over insurance coverage for thousands of product liability lawsuits claiming that a 3M post-surgery warming device caused patients to develop infections.

Expert Analysis

  • Series

    Watching Hallmark Movies Makes Me A Better Lawyer

    Author Photo

    I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.

  • New Orphan Drug Law Provides A Key Fix For Pharma Cos.

    Author Photo

    The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.